Myriad Genetics

• 8-KLeadership change

  Filed Oct 9

  Brian Donnelly’s separation agreement provides severance and accelerated time-based equity in exchange for a claims release and restrictive covenants.

• 8-KGuidance reaffirmedLeadership change

  Filed Sep 16

  Vishal Sikri moves from product to commercial leadership, replacing Brian Donnelly; FY2026 guidance reaffirmed.

• 10-QQ2 FY2026NegativeLegal / investigation

  Filed Jul 31

  Reimbursement pressure and collection-estimate revisions outweighed higher cancer-care and mental-health test volumes.

  • Revenue$190.7MYoY −10.5%
  • Net income−$43.2MYoY +86.9%

• 8-KNegativeEarningsGuidance lowered

  Filed Jul 30

  Lower Prenatal Health volumes and payer friction drive a revenue outlook cut and suspension of Adjusted EBITDA guidance.

• 8-KLeadership change

  Filed Jun 23

  Daniel M. Skovronsky resigned from the board effective June 17, 2026.

• 8-KExecutive payShareholder vote

  Filed Jun 4

  Stockholders expanded the employee stock purchase plan and approved a new equity incentive plan replacing the 2017 plan.

• 10-QQ1 FY2026Impairment / charge

  Filed May 6

  Mental Health growth and more Cancer Care tests offset Prenatal weakness, but lower Cancer Care revenue per test limited gains.

  • Revenue$200.4MYoY +2.3%
  • Net income−$34.1MYoY −34000.0%

• 8-KEarningsGuidance reaffirmedImpairment / charge

  Filed May 5

  Cancer Care Continuum growth and better GeneSight reimbursement offset Prenatal Health declines tied to order-system disruption

• 10-KFY2025NegativeCEO/CFO changeImpairment / charge

  Filed Feb 24

  UnitedHealthcare’s GeneSight coverage change drove revenue lower despite higher test volume; impairments widened the GAAP loss.

  • Revenue$824.5MYoY −1.6%
  • Net income−$365.9MYoY −187.4%

• 8-KEarningsGuidance reaffirmedImpairment / charge

  Filed Feb 23

  UnitedHealthcare’s coverage change hit GeneSight sales and offset Q4 growth; Prenatal volume fell amid an order-system transition.

• 8-KPositiveEarningsNew guidance

  Filed Jan 12

  Hereditary cancer and mental health test volumes rose as prenatal fell; new FY2026 margin guidance incorporates product-launch impacts.

Coverage: 10-K filings filed since Feb 24, 2026; 10-Q since May 6, 2026; 8-K since Jan 12, 2026.

Request longer coverage

Company data: Wikidata Q3331496